Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ARMP
stocks logo

ARMP

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2025Q3
FY2025Q4
1.38M
+42.86%
--
--
1.38M
-53.58%
--
--
1.48M
+19.84%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Armata Pharmaceuticals, Inc. (ARMP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 108.42%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+108.42%
In Past 3 Month
Wall Street analysts forecast ARMP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARMP is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ARMP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARMP is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.940
sliders
Low
9.00
Averages
9.00
High
9.00
Current: 5.940
sliders
Low
9.00
Averages
9.00
High
9.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$9
2025-10-22
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$9
2025-10-22
maintain
Buy
Reason
H.C. Wainwright reiterates a Buy rating and $9 price target on Armata Pharmaceuticals after the company shared new data from the recently completed Phase 2a diSArm study in a late-breaking oral presentation at IDWeek 2025. These new in vitro data providing strong evidence for the efficacy of its core therapeutic strategy for AP-SA02, along with the broader dataset, support advancement into a pivotal Phase 3 trial set to begin in 2026, the analyst tells investors.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$7 -> $9
2025-05-19
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$7 -> $9
2025-05-19
maintain
Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$7
2024-12-19
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$7
2024-12-19
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Armata Pharmaceuticals Inc (ARMP.A) is -3.86, compared to its 5-year average forward P/E of -2.96. For a more detailed relative valuation and DCF analysis to assess Armata Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.96
Current PE
-3.86
Overvalued PE
-1.40
Undervalued PE
-4.52

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.32
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.94
Undervalued EV/EBITDA
-5.69

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
25.86
Current PS
0.00
Overvalued PS
56.35
Undervalued PS
-4.63
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

ARMP News & Events

Events Timeline

(ET)
2025-11-12
16:09:07
Armata Pharmaceuticals announces Q3 earnings per share of (74c), compared to (15c) in the previous year.
select
2025-11-10 (ET)
2025-11-10
07:22:04
Armata Reveals Launch of cGMP Manufacturing Facility in Los Angeles
select
2025-10-22 (ET)
2025-10-22
11:32:07
Armata Pharmaceuticals Rises 19% Following diSArm Study Results Announcement
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-07NASDAQ.COM
Coherus Oncology (CHRS) Posts Q3 Loss and Falls Short of Revenue Projections

  • Quarterly Performance: Coherus Oncology reported a quarterly loss of $0.33 per share, slightly worse than the Zacks Consensus Estimate of a loss of $0.32, and significantly down from a loss of $0.01 per share a year ago.

  • Revenue Miss: The company generated revenues of $11.57 million for the quarter, missing the consensus estimate by 5.23% and down from $70.77 million in the same quarter last year.

  • Stock Outlook: Coherus Oncology's stock has underperformed compared to the S&P 500 this year, and its future performance will depend on management's commentary and earnings estimate revisions, currently holding a Zacks Rank #3 (Hold).

  • Industry Context: The Medical - Biomedical and Genetics industry is ranked in the top 41% of Zacks industries, indicating potential for better performance, while another industry peer, Armata Pharmaceuticals, is expected to report a significant loss in its upcoming results.

[object Object]
Preview
9.0
10-23NASDAQ.COM
Armata Pharmaceuticals (ARMP) Soars 103.2%: Could This Signal More Upside Ahead?

  • Armata Pharmaceuticals Stock Surge: Armata Pharmaceuticals (ARMP) shares rose 103.2% to $7.05 following positive mid-stage results for its bacteriophage therapy, AP-SA02, which showed higher cure rates for Staphylococcus aureus infections compared to placebo.

  • Future Plans and Investor Optimism: The encouraging results have led to plans for a pivotal phase III study in 2026, pending FDA alignment, which has fueled investor optimism regarding the company's potential in next-generation antibacterial therapeutics.

  • Earnings Expectations: Armata is expected to report a quarterly loss of $0.42 per share, a significant decline from the previous year, with revenues projected at $1.38 million, down 53.5% year-over-year.

  • Quantum Computing Developments: The article also highlights the rapid advancement of quantum computing, with major tech companies integrating it into their infrastructure, and mentions a report identifying stocks poised to lead in this emerging field.

[object Object]
Preview
9.0
10-23TipRanks
Reasons Behind the 300% Surge in Armata Pharmaceuticals Stock (ARMP) Today

  • Stock Surge: Armata Pharmaceuticals (ARMP) stock surged nearly 300% after positive mid-stage trial results for its antibacterial therapy, AP-SA02, targeting Staphylococcus aureus bacteremia.

  • Trial Results: In a 42-patient Phase 2a diSArm study, 88% of patients receiving AP-SA02 showed improvement by Day 12, compared to 58% in the placebo group, with no serious side effects reported.

  • Future Plans: The company plans to initiate a pivotal Phase 3 trial in 2026, pending FDA feedback, as part of its strategy to combat antibiotic-resistant infections.

  • Analyst Outlook: H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on ARMP with a $9 price target, indicating a potential upside of 29.12% based on the trial data.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Armata Pharmaceuticals Inc (ARMP) stock price today?

The current price of ARMP is 5.94 USD — it has decreased -0.83 % in the last trading day.

arrow icon

What is Armata Pharmaceuticals Inc (ARMP)'s business?

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The Company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.

arrow icon

What is the price predicton of ARMP Stock?

Wall Street analysts forecast ARMP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARMP is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Armata Pharmaceuticals Inc (ARMP)'s revenue for the last quarter?

Armata Pharmaceuticals Inc revenue for the last quarter amounts to 1.16M USD, decreased -61.02 % YoY.

arrow icon

What is Armata Pharmaceuticals Inc (ARMP)'s earnings per share (EPS) for the last quarter?

Armata Pharmaceuticals Inc. EPS for the last quarter amounts to -0.74 USD, increased 393.33 % YoY.

arrow icon

What changes have occurred in the market's expectations for Armata Pharmaceuticals Inc (ARMP)'s fundamentals?

The market is revising No Change the revenue expectations for Armata Pharmaceuticals, Inc. (ARMP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 108.42%.
arrow icon

How many employees does Armata Pharmaceuticals Inc (ARMP). have?

Armata Pharmaceuticals Inc (ARMP) has 60 emplpoyees as of December 05 2025.

arrow icon

What is Armata Pharmaceuticals Inc (ARMP) market cap?

Today ARMP has the market capitalization of 216.26M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free